INR Above or Below the Therapeutic Range
Increased INR, Coumadin over-dosage; low INR, inadequate Coumadin dosage
Clinical conditions that increase Coumadin effect and elevate INR include:
Low vitamin K intake
Poor nutritional state
Congestive heart failure
Connective tissue diseases
Conditions known to decrease Coumadin effect and decrease INR include:
High vitamin K intake
Many drugs are known to increase warfarin effect and elevate INR:
Effects may be dose-dependent & may not occur in all pts receiving Coumadin & the drug mentioned.
Drugs in this category include carbenicillin, allopurinol, erythromycin, indomethacin, ibuprofen, fluconazole, fenoprofen, isoniazid, ketoconazole, naproxen, metronidazole, phenylbutazone, moxalactam, cephalosporins, trimethoprim-sulfa (Bactrim), amiodarone, quinidine, cimetidine, clofibrate, lovastatin, omeprazole, phenytoin, tamoxifen, thyroxine, quinolones, rofecoxib, celecoxib.Drugs that can decrease warfarin effect & lower INR in some pts include antacids, antihistamines, barbiturates, rifampin, sucralfate, trazodone, carbamazepine, cholestyramine, griseofulvin, haloperidol, oral contraceptives, penicillin, dicloxacillin, and nafcillin.
Suggested Additional Lab Testing
Most important: INR value on a daily basis until patient shows a consistent value within therapeutic range at least 2 or 3 times.
Monitoring is then less frequent but at least 1 times per month.
Lab tests may be helpful in uncovering other conditions, such as liver disease, which lowers the level of coagulation factors and makes therapeutic anticoagulation difficult. Pharmacogenomics testing is a consideration, either before initiation of warfarin, shortly after initiation, or for patients with apparent hypersensitivity to warfarin.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pembrolizumab and Chemotherapy Combination Significantly Improves PFS in NSCLC
- Daratumumab and Elotuzumab: Potential mAb Therapies for Multiple Myeloma
- Sex Hormone Levels Significantly Affect Treatment-Free Survival in Chronic Lymphocytic Leukemia
- Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia
- Pediatric CML: Life-Long Considerations With TKI Therapy
- Nelarabine May Improve Disease-Free Survival in Pediatric and Young Adult T-cell ALL
- Lung Cancer Screening Rates Inadequate in United States Despite USPSTF Recommendations
- Can Oncolytic Viruses Improve Immunotherapies?
- Cognitive Behavioral Therapy Compared With Acupuncture for Insomnia in Cancer Survivors
- CYCORE System May Improve Radiotherapy-Associated Symptoms in Head and Neck Cancer